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Abstract
Background: High fat diet impairs nitric oxide (NO) bioavailability, and induces insulin resistance. The link between
NO availability and the metabolic adaptation to a high fat diet is not well characterized. The purpose of this study
was to investigate the effect of high fat diet on metabolism in mice with decreased (eNOS-/-) and increased
(DDAH overexpressed) NO bioavailability.
Methods: eNOS-/- (n = 16), DDAH (n = 24), and WT (n = 19) mice were fed a high fat diet (HFD) for 13 weeks.
Body weight, biochemical parameters, adipokines and insulin were monitored. The matrigel in vivo model with
CD31 immunostaining was used to assess angiogenesis.
Gene expression in adipose tissues was analyzed by microarray and Real Time PCR. Comparisons of the mean
values were made using the unpaired Student t test and p < 0.05 were considered statistically significant.
Results: eNOS-/- mice gained less weight than control WT and DDAH mice. In DDAH mice, a greater increase in
serum adiponectin and a lesser increment in glucose level was observed. Fasting insulin and cholesterol levels
remained unchanged. The angiogenic response was increased in DDAH mice. In adipose tissue of DDAH mice,
genes characteristic of differentiated adipocytes were down-regulated, whereas in eNOS-/- mice, genes associated
with adipogenesis, fatty acid and triglyceride synthesis were upregulated.
Conclusions: Our results indicate that increased NO availability attenuates some HFD induced alterations in
metabolism and gene expression associated with insulin resistance.
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Background
Nitric oxide synthase (NOS) metabolizes L-arginine to
L-citrulline and nitric oxide (NO), a key regulator of
vascular and metabolic homeostasis. In the vasculature,
the endothelial isoform (eNOS) exerts significant control
over vessel tone, structure and interaction with circulat-
ing blood elements. Endothelium-derived NO is a potent
vasodilator, diffusing into the underlying vascular
smooth muscle to activate soluble guanylate cyclase,
producing the second messenger cGMP [1]. Further-
more, NO is an angiogenic agent. Endothelial cell
survival, proliferation, and migration are required for
angiogenesis, and are promoted by NO [2]. As a signal-
ing molecule low concentrations of NO (10-150 nmol/l)
play a physiological role as an intra- and intercellular
messenger [3]. For example, NO regulates metabolic
lipid and carbohydrate metabolism [4,5]. Glucose meta-
bolism is enhanced by NO, in part by upregulation of
the Glut transporter, and possibly by enhanced vascular
delivery of glucose to insulin sensitive tissues [6,7]. The
importance of NO in vascular and metabolic homeosta-
sis is highlighted by the observation that eNOS deficient
mice have lower NO level [8], are hypertensive and
insulin resistant [9,10]. A decreased production of NO
by the mitochondrial form of NOS (mtNOS) has been
proposed as a cause of decreased mitochondrial
* Correspondence: urazny@cm-uj.krakow.pl
1Department of Clinical Biochemistry, Jagiellonian University Medical College,
Kopernika 15a Street, 31-501 Cracow, Poland
Full list of author information is available at the end of the article
Razny et al. Cardiovascular Diabetology 2011, 10:68
http://www.cardiab.com/content/10/1/68
CARDIO
VASCULAR 
DIABETOLOGY
© 2011 Razny et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.biogenesis, resulting in impairment of cellular turnover,
tissue regeneration (heart, brain, liver) and aging [11,12].
On the other hand at high concentrations (>300 nmol/l)
NO behaves as the cytotoxic molecule promoting the
generation of hydroxyl radicals (HO*) [13].
Asymmetric dimethylarginine (ADMA) is an arginine
analogue that acts as an endogenous inhibitor of the
NOS pathway [14]. The enzyme dimethylarginine
dimethylaminohydrolase (DDAH) degrades ADMA to
citrulline and dimethylamine, and exists as two isoforms
(DDAH-1 and -2) [15,16]. Whereas deficiency of either
isoform is lethal, the heterozygous deficient animals
manifest increased plasma levels of ADMA, synthesize
l e s sN O ,a n da r eh y p e r t e n s i v e[ 1 7 ] .B yc o n t r a s t ,m i c e
that over express DDAH-1 have lower ADMA levels,
greater NOS activity and in consequence higher NO
levels [18] and lower blood pressure. Intriguingly, these
mice are also insulin sensitive [19].
A HFD is known to impair NO stability and synthesis,
and to induce insulin resistance. We were interested to
know if differing basal capacities to generate NO would
affect the metabolic adaptation to a HFD. Accordingly,
we studied the response to a HFD of normal C57Bl6J
mice; those that were deficient in NO synthesis
(eNOS-/-); and those that had enhanced NO synthesis
(DDAH-1 overexpression).
Methods
Mice
The eNOS deficient animals eNOS-/- (B6.129P2-Nos3t-
m1Unc/J) were purchased from Jackson Laboratory
( U S A ) ,a n dt r a n s g e n i cD D A Hm i c eC 5 7 B L / 6 J - T G
(ACTB-DDAH1)1Jpck/J from Charles River Laboratories
(Sulzfeld, Germany).
The eNOS-/- transgenic mice lack endothelial nitric
oxide synthase activity. The mice were created using a
construct that replaced 129 bp of exon 12 of the Nos3
(eNOS) gene with a 1.2 kb neomycin cassette so as to
disrupt calmodulin binding [10].
The transgenic DDAH mice were offspring of control
females and DDAH transgenic males overexpressing
dimethylarginine dimethylaminohydrolase. The mice
were created using a construct encoding human DDAH
I cDNA, a human B-actin promoter, and RNA proces-
sing signals from SV40 derived from a modified human
agouti expression vector [15], called in this work
“DDAH mice”. The C57BL/6J mice are the background
s t r a i nf o rD D A Ha sw e l la st h ee N O S - / -a n i m a l sa n d
they served as control animals.
Animals were housed in cages (22°C and 12 hour daylight
cycle) and were fed standard rodent feed (9 en% of fat)
(Gam-rat, Lublin, Poland). At the age of 6 weeks, C57BL/6J
(n = 19), eNOS-/- (n = 16) and DDAH (n = 24) female
mice were entered into the experimental protocol and fed a
high saturated fat diet (coconut oil hydrogenated based, 39
en% of fat) (MP Biomedicals, Solon, Ohio, USA) for 13
weeks ad libitum. During that period we monitored body
weight (3 times weekly), feed consumption (once weekly),
and blood biochemical parameters (every 2 weeks).
This study was conducted according to National Insti-
tutes of Health Guide for the Care and Use of Labora-
t o r yA n i m a l sa n dw a sa p p r o v e db yt h eI n s t i t u t i o n a l
Animal Care Committee. All experimental protocols
and procedures were approved by the Local University
Ethic Committee in Cracow (No 83/OP/2005) and per-
formed in accordance with the policies regarding the
human care and use of laboratory animals. The per-
formed research was in compliance with ARRIVE guide-
lines on animal research [20].
Biochemical parameters
The serum glucose, triglycerides and total cholesterol con-
centrations were measured (Cormay Diagnostic Kit; Lublin,
Poland) in blood samples collected from the tail vein, after
4 hours of fasting. In addition serum concentrations of
insulin, leptin and adiponectin concentrations were mea-
sured at age 6 and 19 weeks by ELISA (Linco Research, St.
Charles, Missouri, USA or R&D Systems, McKinley Place
NE Minneapolis, USA) [21]. Intra- and interassay coeffi-
cients of variation (CV) were 8,35 and 17,9% for insulin,
4,3 and 7,6% for leptin, 6,6 and 6,4% for adiponectin.
In order to assess insulin sensitivity, the following
indices were calculated: homeostasis model assessment
(HOMA) and quantitative insulin sensitivity check index
(QUICKI). Both indices are based on the fact that the
relationship between glucose and insulin in the basal
state reflects the balance between hepatic glucose output
and insulin secretion. QUICKI and HOMA indexes were
calculated as described previously [22]: QUICKI = 1/[log
(I) + log(G)], where I is fasting insulin (mU/l) and G is
fasting glucose (mg/dl).; HOMA = G * I/22.5, where I is
fasting insulin (mU/l) and G is fasting glucose (mmol/l).
Subcutaneous matrigel model of angiogenesis
Six days before the end of the feeding period, mice
received subcutaneous injections of 0.5 ml matrigel (Bec-
ton Dickinson, Franklin Lakes, New Jersey, USA) contain-
ing basic fibroblast growth factor (bFGF, 25 nmol/l final
concentration) (Sigma-Aldrich, St. Louis, Missouri, USA)
[23]. After 6 days mice were killed and matrigel plugs
were excised with surrounding tissue and preserved for
immunohistochemical staining with rat anti-mouse CD31
(PECAM1) antibody (Becton Dickinson, Franklin Lakes,
New Jersey, USA) [24]. Angiogenic response was esti-
mated by the amount of PECAM1-positive structures and
expressed as the number of vessels with or without a
lumen as well as number of individual PECAM1-positive
cells counted with a Hot Spots method (5 frames per slide
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that was blinded to the experimental groups.
Collection of adipose tissue
After mice were killed samples of inguinal white (WAT)
and brown adipose tissue from the interscapular area
(BAT) were preserved in Trizol Reagent (Invitrogen,
Carlsbad, California, USA) for gene expression analysis.
Analysis of gene expression
For gene expression analysis mRNA was isolated from
white or brown adipose tissues using Trizol Reagent (Invi-
trogen, Carlsbad, California, USA) and purified with
QIAamp RNA for total RNA isolation system (Qiagen,
Valencia, California, USA). The quality of RNA was con-
firmed by denaturing gel electrophoresis and an analysis
on the Agilent 2100 Bioanalyser (Agilent Technologies,
Foster City, California, USA). High grade RNA was used
for hybridization with NuGO oligonucleotide microarrays
(NuGO_Mm1a520177) designed by NuGO and manufac-
tured by Affimetrix (Fremont, California, USA). The
microarray assay was used to evaluate the effects of
impaired (mice eNOS-/-) and enhanced (DDAH -1 over-
expressing mice) NO synthase activity on genes involved
in the metabolism of white or brown adipose tissue. Com-
parison of relative gene expression for eNOS-/- versus
DDAH mice (white and brown adipose tissues separately)
were calculated using GCOS 1.4 software (Affymetrix, Fre-
mont, California, USA). Results from the microarray were
presented as relative gene expression values (fold change).
Only genes for which expression was significantly regu-
lated more than 1.4 fold were analyzed further.
Most of the significantly regulated genes related to
angiogenesis, adipogenesis, fatty acid synthesis, nuclear
receptors in lipid/glucose metabolism and cytotoxicity.
These findings were confirmed by quantitative real-time
PCR (qRT-PCR). Gapdh was used as a reference gene.
Statistical Analysis
Results are shown as mean value ± standard deviation
(SD). Changes in the serum levels of cytokines and adi-
pokines are presented as Δ value between the initiation
of the dietary intervention (at 6 weeks) and sacrifice of
the animals (19 weeks). Comparisons of the mean values
were made using the unpaired Student t test and p <
0.05 were considered statistically significant.
Microarrays were analyzed with Affymetrix Microarray
Analysis Suite. Changes in relative gene expression were
calculated as a rate of case strain (eNOS-/- or DDAH)
against controls (C57/BL/6J) using GeneChip Operating
Software (GCOS 1.4). Only genes with significant differ-
ences in signal intensity of at least 1.4 fold and p < 0.05
were included for further analysis. Analysis of regulated
pathways was performed using Genemap software.
Results
Body composition, biochemical parameters
Body mass measurements revealed that eNOS deficient
mice gained less weight by comparison to control C57
(WT) and DDAH mice (Figure 1). The 13 weeks of the
high fat diet (HFD) was associated with an increase in
blood serum glucose by over 2 mmol/l in the control
mice (Figure 2A). A smaller increment was observed in
e N O S - / -m i c ew h i l ei nt h eD D A Hg r o u pt h e r ew a s
almost no increase in glucose concentration (Figure 2A).
Differences between DDAH and control mice were sta-
tistically significant. The high fat diet caused similar ele-
vations in serum cholesterol levels (by 1.2 - 1.7 mmol/l)
in each group. Triglyceride levels fluctuated during the
feeding period and there were no differences between
mouse strains (data not shown).
There were no significant differences between groups
in insulin levels before or after dietary intervention
(Figure 2B) (Table 1). The high fat diet caused similar
increases in measures of insulin resistance in each
strain. The high fat diet induced a reduction in the
QUICKI (Figure 3A) and an increase in the HOMA
indices (Figure 3B) in all groups, consistent with dietary
induced insulin resistance (Table 1).
Nevertheless, serum levels of adipokines revealed some
intriguing group differences. In the DDAH transgenic
mice, we observed a greater increase in serum adiponec-
tin levels by comparison to control and eNOS-/- mice.
The levels of this adipokine decreased during the feed-
ing period from 9.7 μg/ml to 7.5 μg/ml in control mice
and from 9.6 μg/ml to 6.6 μg/ml in eNOS-/- mice (Fig-
ure 4). No group differences in leptin levels were
observed before or after the dietary intervention.
Figure 1 Changes in body weight. Control C57BL/6J (n = 19),
eNOS-/- (n = 16) and DDAH (n = 24) mice were fed with high fat
diet during 13 weeks. Values are expressed as means ± SEM;
significance *p < 0.05; **p < 0.01.
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The angiogenic response was enhanced in the DDAH
animals. In the subcutaneous matrigel plugs, the num-
ber of vessels with a lumen, the number of vessels
w i t h o u tal u m e na sw e l la st h en u m b e ro fs i n g l e
PECAM1 positive cells was significantly higher in
D D A Ht r a n s g e n i cm i c eb yc o m p a r i s o nt oc o n t r o lo r
eNOS-/- mice. There were no differences in the angio-
genic response to matrigel between eNOS deficient
mice and controls (Figure 5).
Effects of HFD on adipose gene expression
Morphology of adipocytes in a d i p o s et i s s u ef r o me N O S
knockout mice and DDAH mice did not differ. The
influence of eNOS deletion and DDAH overexpression
Figure 2 Changes of serum glucose (A) and insulin levels (B).
The C57BL/6J (n = 19), eNOS-/- (n = 16), DDAH (n = 24) animals
were fed a high fat diet for 13 weeks. Values are expressed as
means ± SEM; significance *p < 0.05.
Table 1 Comparison of biochemical parameters amongst C57, eNOS-/- and DDAH mice before (baseline) and after
feeding a high fat diet (week 13)
C57 eNOS-/- DDAH
baseline 13 week baseline 13 week baseline 13 week
Glucose [mmol/l] 8.34 ± 2.20 9.91 ± 1.31* 8.80 ± 1.07 9.89 ± 1.15 9.14 ± 1.94 9.28 ± 1.92*
Insulin [mU/l] 7.91 ± 5.04 10.07 ± 4.32 5.52 ± 2.40 11.51 ± 6.24** 6.24 ± 3.84 10.55 ± 5.52*
QUICKI
a 0.52 ± 0.07 0.44 ± 0.02* 0.52 ± 0.07 0.46 ± 0.07** 0.54 ± 0.09 0.45 ± 0.05*
HOMA
b 0.27 ± 0.17 0.51 ± 0.19** 0.25 ± 0.13 0.49 ± 0.31** 0.24 ± 0.16 0.51 ± 0.32**
aQUICKI = 1/[log(I) + log(G), where I is fasting insulin (mU/l) and G is fasting glucose (mg/dl)
bHOMA = G * I/22.5, where I is fasting insulin (mU/l) and G is fasting glucose (mmol/l)
*p < 0.05; **p < 0.01: significance between baseline and after13 weeks of feeding (week 13)
Figure 3 Insulin sensitivity of C57BL/6J (n = 19), eNOS-/- (n =
16) and DDAH (n = 24) mice. Insulin sensitivity was shown at
baseline and after 13 weeks of feeding with a high saturated fat
diet. Values are expressed as means ± SEM, *p < 0.05; **p < 0.01,
significance between baseline and 13 weeks of feeding with a high
fat diet. (A) Quantitative insulin sensitivity check index (QUICKI)
(baseline and after 13 weeks of high fat diet feeding). QUICKI = 1/
[log(I) + log(G), where I is fasting insulin (mU/l) and G is fasting
glucose (mg/dl). (B) Homeostasis model assessment (HOMA)
(baseline and after 13 weeks of high fat diet feeding). HOMA = G *
I/22,5, where I is fasting insulin (mU/l) and G is fasting glucose
(mmol/l).
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adipose tissue are presented in Table 2, 3, 4, 5, 6.
Pro-adipogenic genes
We observed distinctly different responses in gene
expression in response to high fat feeding (Table 2). In
the eNOS knockout (ko) mice, the expression of proadi-
pogenic (and the adipocyte differentiation markers)
genes were increased in WAT (Cebpa, Cebpb, Ppadb,
Foxo1, Nr2f1, Mef2d, Ncor, Tgfb, Gdf10, Ucp1, Glut4),
and BAT (Cebpd, Klf6, Klf7, Id3, Fabp). By contrast, in
the DDAH transgenic animals, there was primarily
downregulation of adipogenic gene expression in WAT
(P p a r a ,P p a r b ,R x r g ,M e f 2 c ,N r i p , K l f 6 ,N r 3 c 1 ,G d f 1 0 ,
Fabp4, Ucp1, Lipe, Agt), and in BAT (Cebpa, Cebpb,
Ppara, Foxo1, Foxo3a, Mef2d, LPL, Il6st). The proadipo-
genic genes Cebpa, Cebpb, Foxo1, Mef2d, Ucp1, Gdf10
were also differentially regulated in BAT and WAT in
eNOS ko (up) versus DDAH transgenic (down) animals.
Lipodystrophy related genes were also induced in WAT
of eNOS ko animals (Lipin1, Agpat2).
Lipid biosynthesis genes
Genes related to fatty acid synthesis (Fasn, Acly) were
up-regulated in WAT of eNOS ko animals, while most
of such genes (Fasn, Acacb, Ech1) were primarily down-
regulated in DDAH animals (Table 3). The fatty acid
synthase gene (Fasn) was differently expressed in the
animal models (upregulated in eNOS ko, while downre-
gulated in the DDAH mice). Triglyceride biosynthesis
related genes were also upregulated in WAT of eNOS
ko animals (Dgat2, Agpat2). HFD increased the choles-
terol biosynthesis genes in WAT of eNOS ko (Hmgcs1,
Mvk, Dhcr7)a n dt h eD D A Hm i c e( Hmgcs1, Fdps, Mvk,
Dhcr7, Lss, Cyp51, Sc5d). By contrast, several cholesterol
biosynthesis genes (Pmvk, Sqle, Dhcrt) were downregu-
lated in BAT of DDAH mice.
Genes involved in lipid and carbohydrate metabolism
By comparison to the control animals, we observed
downregulation of the expression of genes related to
beta-oxidation of fatty acids in the DDAH mice (Hadha,
Acads, Acadvl, Slc25a20, Tpi1, Gyk, Crat, Cpt2,Cpt1b)
(Table 3).
The insulin-signaling related genes (were upregulated in
WAT of eNOS ko animals (P l k 3 r 2 ,I l k ,A c t n ,F l n a ,Z y x ,
Vasp, Akt2, Gsk3b), while downregulated in the DDAH
animals (Plk3r1, Plk3ca, Pten, Flna, Sgk) (Table 4).
Long-term HFD feeding resulted in the upregulation
of genes related to glycolysis/gluconeogenesis (Eno3,
Gpi1, Aldoa) in WAT of eNOS ko, whereas some of
these were downregulated in BAT of DDAH animals
(Table 4).
Figure 4 Changes in serum adiponectin concentration.T h e
C57BL/6J (n = 19), eNOS-/- (n = 16), DDAH (n = 24) animals were
fed a high fat diet for 13 weeks. Values are expressed as means ±
SEM; significance *p < 0.05, **p < 0.01.
Figure 5 Angiogenic response in matrigel plug from C57BL/6J
(n = 19), eNOS-/- (n = 16), DDAH (n = 24) mice. Values are
expressed as means ± SEM; significant increase in DDAH compared
to control (C57) and eNOS-/- mice *p < 0.05, **p < 0.01. (A) The
number of CD31 (PECAM1) positive vessel like structures in matrigel
plug of control C57BL/6J (n = 19), eNOS-/- (n = 16) and DDAH (n =
24) mice. (B) The number of single CD31 (PECAM1) positive cells
present in matrigel plug of C57BL/6J (n = 19), eNOS-/- (n = 16) and
DDAH (n = 24) mice.
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Page 5 of 14Table 2 Relative changes in gene expression connected with adipogenesis for white (WAT) and brown (BAT) adipose
tissues of eNOS -/- and DDAH animals vs. control mice
WAT BAT
eNOS-/- DDAH eNOS-/- DDAH
Adipogenesis
CCAAT/enhancer binding protein (C/EBP) Cebpa ↑ ↓
Cebpb ↑ ↓
Cabpd ↑
peroxisome proliferator activated receptor alpha Ppara ↓↓
peroxisome proliferator-activated receptor gamma Pparg ↓#
peroxisome proliferator-activated receptor beta Pparb ↑
retinoid X receptor gamma Rxrg ↓
forkhead box O Foxo1 ↑↑ ↓
Foxo3a ↓
myocyte enhancer factor Mef2c ↓
Mef2d ↑ ↓
nuclear receptor subfamily 2, group F, member 1 Nr2f1 ↑
nuclear receptor interacting protein Nrip ↓↓ ↑
nuclear receptor co-repressor Ncor ↑
transforming growth factor, beta Tgfb ↑
insulin-like growth factor 1 Igf1 ↑
Kruppel-like factor 6 Klf6 ↓ ↑
Kruppel-like factor 7 Klf7 ↑
nuclear receptor subfamily 3, group C, member 1 Nr3C1 ↓
prolactin receptor Prlr ↓
early B-cell factor 1 Ebf1 ↓
growth differentiation factor 10 Gdf10 ↑ ↓
catenin (cadherin associated protein) Catnb ↑↑
early growth response Egr ↑
zinc finger, HIT type 3 Trip3 ↑
stearoyl-Coenzyme A desaturase 1 Scd1 ↑
inhibitor of DNA binding 3 Id3 ↑
phosphoenolpyruvate carboxykinase 1, cytosolic Pck1 ↑
interleukin 6 signal transducer Il6st ↓
Adipocyte differentiation markers
fatty acid binding protein 4 Fabp4 ↓↓ # ↑
uncoupling protein 1 Ucp1 ↑# ↓# ↓#
lipoprotein lipase LPL ↓# ↓#
lipase, hormone sensitive Lipe ↓↓
facilitated glucose transporter Glut4 ↑# ↓#
Adipocyte secretion products
angiotensinogen Agt ↓↓
adipsin Adn ↓
adipophilin Adfp ↓
↑ - upregulated genes; ↓ - downregulated genes; # - genes which expression was confirmed by real time PCR
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Page 6 of 14Table 3 Relative changes in gene expression related to lipid metabolism for white (WAT) and brown (BAT) adipose
tissues of eNOS -/- and DDAH animals vs. control mice
WAT BAT
eNOS-/- DDAH eNOS-/- DDAH
Lipodystrophy related genes
lipin Lipin1 ↑ ↓
lysophosphatidic acid acyltransferase, beta Agpat2 ↑ ↓
zinc metallopeptidase Zmpste24 ↓
Bernardinelli-Seip congenital lipodystrophy Bscl2 ↓
Cholesterol synthesis
hydroxymethylglutaryl-CoA synthase 1 Hmgcs1 ↑↑
farnesyl diphosphate synthetase Fdps ↑ ↓
phosphomevalonate kinase Pmvk ↓
mevalonate kinase Mvk ↑↑
squalene epoxidase Sqle ↓↓
7-dehydrocholesterol reductase Dhcr7 ↑↑ ↓
lanosterol synthase Lss ↑
cytochrome P450, family 51 Cyp51 ↑
sterol-C5-desaturase Sc5d ↑
Triglyceride synthesis
diacylglycerol O-acyltransferase Dgat1 ↓
Dgat2 ↑
lysophosphatidic acid acyltransferase, beta Agpat2 ↑
Fatty acid synthesis
fatty acid synthase Fasn ↑# ↓# ↓#
stearoyl-Coenzyme A desaturase Scd ↑
ATP citrate lyase Acly ↑ ↓
acetyl-Coenzyme A carboxylase beta Acacb ↓↓ ↓↓
mitochondrial trans-2-enoyl-CoA reductase Nrbf1 ↓
enoyl coenzyme A hydratase 1 Ech1 ↓
Fatty acid beta-oxydation
patatin-like phospholipase domain containing 2 Pnpla2 ↓
mitochondrial trifunctional protein, alpha subunit Hadha ↓↓
fatty acid Coenzyme A ligase Acsl1 ↓
Acsl3 ↓
Acsl5 ↓
carnitine palmitoyltransferase 1a Cpt1a ↑
acyl-Coenzyme A dehydrogenase Acads ↓
Acadvl ↓
mitochondrial carnitine/acylcarnitine translocase Slc25a20 ↓
triosephosphate isomerase 1 Tpi1 ↓
glycerol kinase Gyk ↓
carnitine acetyltransferase Crat ↓
carnitine palmitoyltransferase 2 Cpt2 ↓
carnitine palmitoyltransferase 1b Cpt1b ↓
↑ - upregulated genes; ↓ -downregulated genes; # - genes which expression was confirmed by real time PCR
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Page 7 of 14Genes related to oxidative stress and angiogenesis
Genes protective against oxidative stress were downregu-
lated in WAT of eNOS ko, (Gstt2,Gyp1a1, Maoa) while
up-regulated (Fos, Sod, Gstt) in the DDAH animals.
Downregulation of such genes (Sod, Gpx,Cat, Txn2)w a s
primarily observed in BAT of DDAH mice (Table 5).
We observed upregulation of some adhesion and cell
survival/proliferation-related genes (in WAT (Lama,
Lamb, Itgam, Birc4, x-linked inhibitor of apoptosis) of
t h eD D A Hm i c ea sw e l la si nt h ee N O Sk oa n i m a l s
(Fn1, Itga7, Itga8, Mmp19, Mmp17, Mylk, Trp53, Bok,
RAF, ERF). Downregulation of some angiogenic genes in
WAT of eNOS and DDAH animals (Thbs2,Tnxb, stro-
melins, Timp4, Nfkbia, vWF) was also observed (Table
5, 6). By comparison to WAT, in BAT tissue the angio-
genic genes were less regulated; however, some genes
for proliferation and antiapoptotic gene expression were
upregulated in the DDAH animals (Pcna, Mpeg1, CCnh,
Fos, X-linked inhibitor of apoptosis).
Discussion
In metabolic disorders associated with atherosclerosis,
NO synthesis and/or stability is reduced [5,6,14].
To determine if NO bioavailability may modulate
the response to a high fat diet, we assessed serum
and genetic markers of metabolism in mice with
decreased (eNOS ko) as well as increased (DDAH) NO
bioavailability.
Table 4 Relative changes in gene expression related to carbohydrate metabolism for white (WAT) and brown (BAT)
adipose tissues of eNOS -/- and DDAH animals vs. control mice
WAT BAT
eNOS-/- DDAH eNOS-/- DDAH
Insulin signaling
insulin receptor substrate Irs1 ↑
Is3 ↓
growth factor receptor bound protein 2-associated protein 1 Gab1 ↓
phosphatidylinositol 3-kinase PIk3r1 ↓↓ ↑
PIk3r2 ↑
PIk3ca ↓
phosphatase and tensin homolog Pten ↓↓
integrin linked kinase Ilk ↑
actinin Actn ↑
vinculin Vcl ↑
filamin Flna ↑ ↓
zyxin Zyx ↑
vasodilator-stimulated phosphoprotein Vasp ↑
RAS-related C3 botulinum substrate 1 Rac1 ↑
AKT/PDK
thymoma viral proto-oncogene 2 Akt2 ↑
serum/glucocorticoid regulated kinase Sgk ↓ ↑
glycogen synthase kinase 3 beta Gsk3b ↑ ↓
m-TOR
tuberous sclerosis Tsc1 ↓
Tsc2 ↑
mechanistic target of rapamycin (serine/threonine kinase) frap1 ↓
ribosomal protein S6 kinase Rps6kb1 ↑↑
Rps6kb2 ↓
eukaryotic translation initiation factor 4E binding protein Eif4ebp1 ↓
Glycolysis/Gluconeogenesis
enolase Eno3 ↑# ↓
glucose phosphate isomerase 1 Gpi1 ↑ ↓
aldolase Aldoa ↑ ↓
↑ - upregulated genes; ↓ -downregulated genes; # - genes which expression was confirmed by real time PCR
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Page 8 of 14Table 5 Relative changes in gene expression connected with oxidative stress and inhibition of angiogenesis for white
(WAT) and brown (BAT) adipose tissues of eNOS -/- and DDAH animals vs. control mice
WAT BAT
eNOS-/- DDAH eNOS-/- DDAH
Anti-Angiogenic genes
Adhesion
thrombospondin 1 Thbs1 ↓
thrombospondin 2 Thbs2 ↓↓
Collagen ↑7subunits ↑3subunits
↓1 subunit
laminin B1 Lamb1-1 ↑
Laminin alpha Lama ↑
Laminin beta Lamb ↑
integrin alpha Itga6 ↓ ↑
Itga7 ↑
Itga8 ↑ ↓
Itgam ↓ ↑
MMP’s
tissue inhibitor of metalloproteinase Timp3 ↓
Timp4 ↓↓ ↓
Apoptosis
nuclear factor of kappa B Nfkbia ↓↓
caspase Casp7 ↓
Casp8 ↑
BCL2-associated X protein Bax ↓
conserved helix-loop-helix ubiquitous kinase Chuk ↑
transformation related protein 53 Trp53 ↑
BCL2-related ovarian killer protein Bok ↑
X-linked inhibitor of apoptosis ↑↑
Oxidative stress
Repression of ROS production
cytochrome b-245, alpha polypeptide Cyba ↑↑
nuclear factor I/X Nfix ↓
glutathione S-transferase, theta 2 Gstt2 ↓
Gtpase activating protein Gyp1a1 ↓
monoamine oxidase A Maoa ↓
Adaptation against existing ROS
FBJ osteosarcoma oncogene Fos ↑↑ ↑
superoxide dismutase 2 Sod ↑ ↓↓
glutathione S-transferase theta Gstt ↑
glutathione peroxidase 3 Gpx ↓
catalase Cat ↓
thioredoxin 2 Txn2 ↓
↑ - upregulated genes; ↓ -downregulated genes; # - genes which expression was confirmed by real time PCR
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capacity influence the response to a HFD as assessed by
glucose and adiponectin levels; the angiogenic response;
and adipose (BAT and WAT) gene expression. The data
suggest that in aggregate, NO activity is protective
against some of the metabolic perturbations induced by
a high fat diet.
Diet-induced insulin resistance
Epidemiological, clinical and basic research studies have
demonstrated that a high fat diet induces insulin resis-
tance. Most studies suggest that increased dietary fat
causes whole-body and regional (liver, adipose tissue,
muscle) insulin resistance in both animals and humans.
Vessby et al. documented that insulin sensitivity was
impaired by 10% in healthy individuals who receive an
isoenergetic diet containing a high content of saturated
fatty acids for 3 months. A change in the composition
of the dietary fatty acids, ie. decreasing saturated fatty
acid and increasing monounsaturated fatty acid content,
improved insulin sensitivity [25]. Substituting 11% of the
saturated fatty acids with short-chain omega-3 fatty
acids (alpha-linolenic acid, 18:3 omega 3) prevented
insulin resistance induced by a saturated-fat diet in rats
[26].
Duplain [9] and Sydow [19] using glucose clamp stu-
dies reported insulin resistance in eNOS ko mice and
increased insulin sensitivity in DDAH transgenic mice.
It has been reported that elevated plasma levels of
ADMA are associated with insulin resistance, micro/
macrovascular diabetic complications, and may predict
cardiovascular events in type 2 diabetic patients. In turn,
Table 6 Relative changes in pro-angiogenic gene expression for white (WAT) and brown (BAT) adipose tissues of eNOS
-/- and DDAH animals vs. control mice
WAT BAT
eNOS-/- DDAH eNOS-/- DDAH
Pro - Angiogenic genes
MMP’s
Stromielins ↓↓
basigin Bsg ↑
Gelatinases ↓
matrix metallopeptidase Mmp19 ↑
Mmp17 ↑
Proliferation
Rho-associated coiled-coil containing protein kinase 1 Rock1 ↑
coatomer protein complex, subunit beta Rack2 ↓
myosin, light polypeptide kinase Mylk ↑ ↓
proliferating cell nuclear antigen Pcna ↑
macrophage expressed gene 1 Mpeg1 ↑
cyclin H CCnh ↑
Jun oncogene Jun ↑ ↓
FBJ osteosarcoma oncogene Fos ↑↑
Cell survival
RAF proteins ↑ ↓ ↑
ERK proteins ↑
X-linked inhibitor of apoptosis Birc4 ↑
Jun oncogene Jun ↑ ↓
Apoptosis ↑
heat shock protein Hspa1a ↑
Adhesion
platelet derived growth factor receptor, alpha Pdgfra ↑
fibronectin Fn1 ↑
tenascin XB Tnxb ↓↓
von Willebrand factor Vwf ↓
↑ - upregulated genes; ↓ -downregulated genes; # - genes which expression was confirmed by real time PCR
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Page 10 of 14Lu et al. documented that some genetic variations in
DDAH1 could contribute to higher risk of type 2 dia-
betes independently of plasma ADMA levels.
For example, SNP (single nucleotide polymorphism)
rs1241321 in DDAH1 was found to be associated with a
higher type 2 diabetes risk independently of plasma
ADMA levels. AA genotype at rs1241321 appeared to
be more insulin-sensitive in comparison to AG/GG indi-
viduals. Thus, the DDAH1 gene could play an important
role in the pathogenesis of type 2 diabetes [27].
In our studies in order to access insulin resistance we
focused on the fasting levels of glucose and insulin. Our
work confirms that a high fat diet rich in saturated fatty
acids induces insulin resistance, which was observed in
all groups. However, the DDAH animals were resistant
to the diet-induced increase in glucose levels observed
in the control animals. This was despite a greater
weight gain in the DDAH transgenic animals in
response to the high fat diet (see discussion below). Pre-
vious studies by Tanaka [18] demonstrated higher NO
level in DDAH mice thus lower glucose levels in the
DDAH transgenic mice reflect the fact that NO is
known to increase glucose transport, in part by increas-
ing the translocation to the cell surface of Glut 4, the
active transporter of glucose [28]. In skeletal muscle
from eNOS ko mice, which according to Kanetsuna stu-
dies present lower NO levels [8], there is diminished
insulin-stimulated glucose uptake, indicating that insulin
activation of NO may contribute to the stimulation of
glucose transport [9].
Furthermore, the DDAH transgenic animals exhibited
higher adiponectin levels. Adiponectin is an adipocyto-
kine that increases glucose uptake, reduces gluconeo-
genesis and lipogenesis, and enhances b-oxidation of fat,
by activating AMPK and PPARa [29]. A characteristic
feature of individuals with diabetes mellitus or insulin
resistance is a decrease of adiponectin levels [30]. There
appears to be a reciprocal relationship between adipo-
nectin and NO. Adiponectin deficient mice exhibit
impaired endothelium-dependent vasodilation [31]. This
is likely due to the fact that adiponectin increases the
stability of eNOS mRNA and half-life, enhances the
association of eNOS with Hsp90 and stimulates the
phosphorylation of eNOS, which together lead to
increased NO production [32,33]. Adiponectin may also
prevent NO degradation by reducing the production of
superoxide anion by endothelial cells [34]. On the other
hand, NO appears to positively regulate adiponectin
levels. Chronic administration of the NOS inhibitor L-
NAME to Sprague-Dawley rats reduces plasma adipo-
nectin levels [35]. Conversely, chronic enhancement of
NO synthesis (the DDAH transgenic mouse) is asso-
ciated with resistance to diet-induced reduction in adi-
ponectin levels (the current study).
High fat diet and angiogenesis
Endothelial NOS activity plays a critical role in angio-
genesis and endothelial function. Survival, proliferation
and migration of endothelial cells, and their secretion of
angiogenic factors, are dependent upon NO [36,37]. The
angiogenic response to ischemia after femoral artery
ligation is impaired in eNOS deficient mice, whereas it
is enhanced in eNOS overexpressing mice [38]. Simi-
larly, after femoral artery ligation, chronic infusion of
ADMA reduces capillary density and perfusion, whereas
DDAH overexpression (associated with lower endogen-
ous ADMA levels) increases angiogenic response and
improves endothelial function [39].
One of the diseases associated with impaired endothe-
lium-dependent NO mediated vasodilation (endothelial
dysfunction) is congestive heart failure (CHF). Coronary
endothelial dysfunction in CHF may be due to decreased
DDAH, which in consequence, leads to a higher ADMA
level [40]. Moreover, Riccioni et al. showed that patients
who received pharmacological treatment for acute con-
gestive HF (diuretics, digoxin, ACE-inhibitors or angio-
tensin receptor blockers, and nitroglicerin), have
significantly higher plasma ADMA levels after pharma-
cological treatment in comparison to pre-treatment.
Such results suggest that acute renal impairment func-
tion and the modulation of NOS determine plasma
ADMA levels after therapy [41].
The current study concentrated on the effect of NO
availability on angiogenesis in mice. To achieve this aim,
another model of angiogenesis, in response to subcuta-
neous administration of matrigel, was used. Consistent
with previous studies, we observed that the vascularity
of the matrigel plug was increased in the DDAH trans-
genic mice, as manifested by a higher number of vessel-
like structures (with and without lumen) as well as a
greater number of PECAM1 positive cells. Since angio-
genesis is crucial for development and growth of all
organs (including adipose), NOS activity may in part
explain the discordance in body weight gain with the
HFD in the different groups. By comparison to the con-
trol mice, the HFD induced a greater weight gain in the
DDAH mice, whereas in the eNOS-/- animals it induced
less weight gain. This observation is consistent with a
previous report that eNOS deficient female mice are
smaller than wild type ones [42].
We were surprised to find that angiogenesis in
response to the matrigel plug was not reduced in the
eNOS-/- mice. It is possible that the matrigel itself, con-
taining a number of angiogenic cytokines including
bFGF [43] potently recruits other angiogenic mechan-
isms, including inflammatory cells carrying iNOS [44]. It
is also possible that in the setting of a HFD, the conco-
mitant inflammation and oxidative stress contribute to
the angiogenic stimulus.
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Adipose tissue is highly vascularized, and each adipocyte
is nourished by an extensive capillary network. Adipose
tissue may be considered as the largest endocrine gland,
as it produces several systemically active adipokines (eg.
leptin, adiponectin, resistin) as well as VEGF, angiopoie-
t i n s ,H G F ,I G F - 1 ,a n g i o g e n i n ,I L - 6 ,T N F - a and fatty
acid metabolites. Many of these may promote the
inflammation and angiogenesis response associated with
adipose tissue accumulation [45]. It is also documented
that adipose tissue endothelial cells promote preadipo-
cyte differentiation [46]. Vascularity of adipose tissue is,
therefore, critical for development, maturation, plasticity
and functions of adipose tissue as a metabolic and an
endocrine organ [47,48]. Thus, it may seem counterin-
tuitive that, if angiogenesis promotes lipogenesis, then
the DDAH animals (which have an enhanced angiogenic
response) have a normalized metabolic state. However,
DDAH overexpression may have additional effects to
offset any metabolic effects of angiogenesis-enhanced
lipogenesis. For example, the reduction in ADMA would
be anticipated to reduce inflammation. Previous studies
have shown that endothelium-derived NO is a potent
anti-inflammatory molecule, suppressing the expression
of chemokines and adhesion molecules mediating
immune cell infiltration [49]. In this regard, there are
data indicating that the number of immune cells in adi-
pose tissue is related to insulin resistance [50]. Alterna-
tively, it could be that reductions in ADMA and
increased NOS activity could have a direct effect on adi-
pose gene expression. In this respect we observed intri-
guing differences between the DDAH and eNOS-/- mice
in adipose gene expression.
NOS activity and adipose gene expression in response to
diet
As shown in Table 2 the expression of markers charac-
teristic for differentiated adipocytes, such as Fabp4,
Ucp1, Lpl or Lipe, were downregulated in DDAH ani-
mals (ie. with higher NO bioavailability). By contrast, we
observed upregulation of genes associated with lipogen-
esis in eNOS deficient mice. In the adipose tissue of
these animals genes regulating adipogenesis (Cebpa,
Cebpb, Ppadb, Foxo1, Nr2f1, Mef2d, Ncor, Tgfb, Gdf10,
Ucp1, Glut4) as well as fatty acid (Fasn, Acly) and trigly-
ceride (Dgat2, Agpat2) synthesis were upregulated. By
comparison to the controls, genes concerning fatty acid
oxidation were downregulated in both groups. The stu-
dies suggest that increased NO availability promotes
changes in adipocyte gene expression, but not in adipo-
genesis. This may explain why, despite greater angio-
genic capacity, the DDAH transgenic mice do not have
greater adipogenesis.
Our microarray analysis of gene expression in WAT
revealed that a number of genes involved in protection
from oxidative stress such as Fos, So d or Gstt were
upregulated in DDAH mice. This might reflect a com-
pensatory response to nitrosative stress that may be
induced by increased concentrations of the free radical
NO [51]. Alternatively, this could reflect direct effects
on gene expression by NO, as cGMP can increase the
expression of superoxide dismutase 2 [52].
The main purpose of adipose tissue (especially WAT)
is storage of high energy compounds [53]. In addition to
regulating vascular tone, nitric oxide plays a crucial role
in regulating metabolism of this tissue. It has been
shown that in adipocytes, hepatocytes and myocytes
nitric oxide activates glucose uptake as well as mito-
chondrial-biogenesis and catabolism (mitochondrial oxi-
dation of glucose and FFA) [7]. These effects are
observed in response to physiological concentrations of
NO, endogenously produced by nNOS and eNOS [54].
These studies suggest a catabolic role for NO. The
recent discovered mitochondrial NOS (mtNOS) may
also play a role, as it maintains a low level of NO gen-
eration in healthy tissue (0.004-4.0 nmol NO min
-1 mg
-1
protein). The mtNOS has significant effects on cellular
turnover, metabolism and survival [11,12].
Conclusions
In summary, we conclude that changes in endogenous
NOS activity alter the metabolic and genetic response to
a high fat diet. An increase in endogenous eNOS activity
(as in the DDAH mouse) is associated with an attenua-
tion or reversal of fat-induced changes in blood sugar,
adipocytokine levels, and adipogenesis gene expression.
By contrast, a reduction in eNOS activity is associated
with an increased susceptibility to fat-induced changes
in gene expression that promote adipogenesis.
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